Evidence map›Paper›PMID 37067945›Full record

ArticleBlood advances2023

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.

Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, Jean Marc Schiano De Colella, Clement Bailly, Salim Kanoun, Stéphanie Guidez, Emmanuel Gyan and 9 more

Erratum issuedAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Yassine Al TabaaScintidoc Nuclear Medicine Center, Clinique Clémentville, Montpellier France.
Rene Oliver CasasnovasHematology, Le Centre Hospitalier Universitaire (CHU) François Mitterrand, Dijon, France.
Clio BailletNuclear Medicine, CHU Lille, Lille, France.
Emmanuel BachyHematology, CHU Lyon, Lyon, France.ORCID 0000-0003-2694-7510
Emmanuelle Nicolas-VirelizierHematology, Centre de Recherche en Cancerologie de Lyon, Lyon, France.
Jean Marc Schiano De ColellaHematology, Institut Paoli-Calmettes, Marseille, France.ORCID 0000-0001-9923-4808
Clement BaillyNuclear Medicine, CHU Nantes, Nantes, France.
Salim KanounTeam 9, Centre de Recherche Clinique de Toulouse, Toulouse, France.
Stéphanie GuidezHematology, CHU Poitiers, Poitiers, France.
Emmanuel GyanHematology and cell therapy Department, CIC INSERM U1415, CHU Tours, University of Tours, Tours, France.ORCID 0000-0002-7651-9189
Remy GressinHematology, CHU Grenoble, Grenoble, France.
Nadine MorineauHematology, CHD Vendée, La Roche sur Yon, France.
Loic YsebaertHematology, Oncopole Toulouse, Toulouse, France.
Steven Le GouillHematology, CHU Nantes, Nantes, France.ORCID 0000-0001-9840-2128
Herve TillyHematology, Centre Henri Becquerel, Rouen, France.
Roch HouotHematology, CHU Rennes, Rennes, France.ORCID 0000-0003-1729-8213
F MorschhauserHematology, CHU Lille, Lille, France.ORCID 0000-0002-3714-9824
Guillaume CartronHematology, CHU Montpellier, Montpellier, France.ORCID 0000-0003-0659-9635
Charles HerbauxHematology, CHU Montpellier, Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunomodulating AgentsLymphomaHumansImmunomodulating Agents

Identifiers

PMID37067945
PMCPMC10368761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.